超声引导下经皮微波消融脾实性病变的罕见队列经验
回顾性纳入2006年10月至2025年4月共34例患者42个脾实性肿瘤,评估超声引导下经皮微波消融的可行性、安全性与疗效。所有病灶技术成功率100%,原发良性组与继发恶性组一年肿瘤体积缩小率超过80%者分别为66.7%和68.4%,恶性组中位总生存114个月。最常见并发症为血小板减少,均无需干预恢复。
要点
- 脾实性病变微波消融技术成功率高,本组42个病灶全部完成消融。
- 术后血小板减少为最常见并发症,多可自行恢复。
- 恶性病变消融后局部进展者可考虑重复消融。
核心结论
- 超声引导下经皮微波消融是选择性脾实性病变患者减瘤且保留脾脏的可行且相对安全的方法。
研究设计与样本
- 回顾性研究,纳入2006年10月至2025年4月行微波消融的34例患者共42个脾实性肿瘤。
- 分为原发良性组15例和继发恶性组19例。
- 主要终点为技术成功率、肿瘤体积缩小率及局部肿瘤进展率,次要终点为总生存和并发症率。
诊断标准与关键数值
- 全部病灶技术成功率为100%。
- 原发良性组66.7%(10/15)患者一年肿瘤体积缩小率超过80%,中位总生存未达到且所有患者存活。
- 继发恶性组68.4%(13/19)患者一年肿瘤体积缩小率超过80%,中位总生存114个月。
- 4例恶性病变患者出现局部肿瘤进展并接受重复消融。
临床应用与阅片要点
- 超声可实时引导穿刺并监测消融范围,适用于希望保留脾脏的实性病变患者。
- 术后需关注血小板计数变化,血小板减少多为自限性,无需特殊干预。
- 恶性病变消融后应随访局部控制情况,进展时重复消融可作为一种处理方式。
局限性
- 回顾性研究设计,单中心罕见队列经验。
- 原文仅提供初步证据,未报告更高级别疗效对比数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the feasibility, safety, and efficacy of ultrasound-guided percutaneous microwave ablation (MWA) for splenic solid lesions.
MATERIALS AND METHODS: A total of 34 patients with 42 splenic tumors who underwent MWA between October 2006 and April 2025 were enrolled in this retrospective study. The primary endpoints were technical success rate, tumor volume reduction rate (VRR), and local tumor progression (LTP) rate. Secondary endpoints included overall survival (OS) and complication rate.
RESULTS: The overall cohort was divided into a primary benign group (n = 15) and a secondary malignant group (n = 19), achieving the total technical success rate of 100% across all lesions. In the primary benign cohort, 66.7% (10/15) of patients achieved tumor VRR over 80% at one year, and the median OS was not reached (all patients remained alive). In the secondary malignant cohort, 68.4% (13/19) showed tumor VRR over 80% at one year, with a median OS of 114 months. Four patients with malignant lesions developed LTP, and received repeated ablation. The most common complication was thrombocytopenia which resolved without intervention.
CONCLUSION: This study provides preliminary evidence that ultrasound-guided percutaneous MWA is a feasible and relatively safe approach for reducing splenic solid lesion burden while preserving spleen in selected patients.
引用
- Luo, Xue, Han, et al. Ultrasound-guided percutaneous microwave ablation of splenic solid lesions: experience in a rare cohort. Abdom Radiol (NY). 2026. PMID: 42622826. doi:10.1007/s00261-026-05742-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。